Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in High-Risk Outpatients With COVID-19 (MAOP3 Trial)

NCT04709328 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT04709328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04709328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in High-Risk Outpatients With COVID-19 (MAOP3 Trial)
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
March 28, 2021
Completion date
March 1, 2022
Enrollment
690 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2